Search
DiaMedica Therapeutics Inc
DMACAdd to Watchlist
6.550USD
+0.080+1.24%
Close 09-11 16:00（ET）
353.21MMarket Cap
LossP/E TTM
DiaMedica Therapeutics Inc (DMAC) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to DiaMedica Therapeutics Inc in the past month.
Buy
0 Strong Buy
5 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
17.000USD+162.75%
DMAC Analyst Recommendation Trends
In the current month, DMAC has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DMAC average Analyst price target in the last month is 17.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
DMAC Analyst Rating for Peer Comparison
Updated: Sep 14, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
12
1
0
0
21
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, DMAC EPS is projected to reach -0.208 in FY2026Q3, following reported EPS of -0.188 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.18
-0.18
-0.20
-0.21
-0.22
Actual
-0.17
-0.19
-0.19
--
--
Surprise
+7.37%
-0.91%
+5.94%
--
--
FAQs
What is DiaMedica Therapeutics Inc's price target?
Analysts forecast that DiaMedica Therapeutics Inc's price target is USD 17.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 12.00.
How have DiaMedica Therapeutics IncDMAC's recent earnings per share performed?
The market expectation was USD -0.19, while DiaMedica Therapeutics IncDMAC's earnings per share (EPS) for the previous quarter was USD -0.19. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for DiaMedica Therapeutics Inc?
Based on the ratings of DiaMedica Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.